Stock Events

Stock Events

Summit Therapeutics 

$14.28
196
+$0.53+3.85% Today

Statistics

Day High
14.4
Day Low
13.7
52W High
30.98
52W Low
12.55
Volume
7,323,302
Avg. Volume
5,023,816
Mkt Cap
11.07B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.76
-0.52
-0.29
-0.05
Expected EPS
-0.274389
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-2.16BNet Income

Analyst Ratings

24.74Average Price Target
The highest estimate is 45.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
17%
Hold
67%
Sell
17%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SMMT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap114.63B
Vertex Pharmaceuticals is a direct competitor in the cystic fibrosis market, where Summit Therapeutics is also aiming to make significant advancements.
Gilead Sciences
GILD
Mkt Cap153.66B
Gilead Sciences competes in the antiviral space, particularly in treatments for HIV, hepatitis B, and hepatitis C, areas where Summit Therapeutics has shown interest.
Abbvie
ABBV
Mkt Cap382.49B
AbbVie competes in the area of infectious diseases and immunology, which overlaps with Summit's research interests.
Merck
MRK
Mkt Cap281.24B
Merck & Co. is involved in developing therapies for infectious diseases, including antibiotics and antivirals, making it a competitor to Summit Therapeutics.
Pfizer
PFE
Mkt Cap143.68B
Pfizer has a broad portfolio that includes treatments for infectious diseases, directly competing with Summit Therapeutics' focus areas.
Astrazeneca
AZN
Mkt Cap271.29B
AstraZeneca has a diverse portfolio that includes treatments for infections, competing with Summit Therapeutics in the infectious disease space.
Johnson & Johnson
JNJ
Mkt Cap549.78B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the area of infectious diseases, an area of focus for Summit Therapeutics.
Novartis
NVS
Mkt Cap280.64B
Novartis competes in multiple therapeutic areas, including those targeted by Summit Therapeutics, such as infectious diseases.
AMGEN
AMGN
Mkt Cap182.21B
Amgen focuses on innovative therapeutics in areas that could overlap with Summit Therapeutics' interests, including treatments for serious illnesses.
Biogen
BIIB
Mkt Cap29.02B
Biogen's focus on novel therapies for neurological and neurodegenerative diseases places it in competition with Summit Therapeutics' broader focus on innovative treatments.

About

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Show more...
CEO
Mr. Robert W. Duggan
Employees
159
Country
United States
ISIN
US86627T1088

Listings

MX
MX
SMMT.MX
XNAS
US
SMMT
BOATS
BOATS
SMMT.BOATS

0 Comments

Share your thoughts

FAQ

What is Summit Therapeutics stock price today?▼
The current price of SMMT is $14.28 USD — it has increased by +3.85% in the past 24 hours. Watch Summit Therapeutics stock price performance more closely on the chart.
What is Summit Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Summit Therapeutics stocks are traded under the ticker SMMT.
Is Summit Therapeutics stock price growing?▼
SMMT stock has risen by +1.06% compared to the previous week, the month change is a -14.08% fall, over the last year Summit Therapeutics has showed a -30.54% decrease.
What is Summit Therapeutics market cap?▼
Today Summit Therapeutics has the market capitalization of 11.07B
When is the next Summit Therapeutics earnings date?▼
Summit Therapeutics is going to release the next earnings report on August 12, 2026.
What were Summit Therapeutics earnings last quarter?▼
SMMT earnings for the last quarter are -0.24 USD per share, whereas the estimation was -0.27 USD resulting in a +10.85% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Summit Therapeutics revenue for the last year?▼
Summit Therapeutics revenue for the last year amounts to 0 USD.
What is Summit Therapeutics net income for the last year?▼
SMMT net income for the last year is -2.16B USD.
How many employees does Summit Therapeutics have?▼
As of June 22, 2026, the company has 159 employees.
In which sector is Summit Therapeutics located?▼
Summit Therapeutics operates in the Health & Wellness sector.
When did Summit Therapeutics complete a stock split?▼
Summit Therapeutics has not had any recent stock splits.
Where is Summit Therapeutics headquartered?▼
Summit Therapeutics is headquartered in Miami, United States.